Patents by Inventor Renske Daniëla Maria Steenbergen

Renske Daniëla Maria Steenbergen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132972
    Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.
    Type: Application
    Filed: October 29, 2023
    Publication date: April 25, 2024
    Inventors: Willem Frederik Rurup, Loes Irene Segerink, Roderik Adriaan Kraaijenhagen, Herbert Michael Pinedo, Albert Van Den Berg, Renske Daniela Maria Steenbergen, Jacobus Adrianus Nieuwenhuijzen, Idris Bahce, Geert Kazemier
  • Patent number: 11821040
    Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: November 21, 2023
    Assignee: Nanomed Diagnostics BV
    Inventors: Willem Frederik Rurup, Loes Irene Segerink, Roderik Adriaan Kraaijenhagen, Herbert Michael Pinedo, Albert Van Den Berg, Renske Daniëla Maria Steenbergen, Jacobus Adrianus Nieuwenhuijzen, Idris Bahce, Geert Kazemier
  • Publication number: 20210172029
    Abstract: The invention relates to methods for detecting the presence of, or risk at, bladder cancer using novel DNA methylation markers for bladder cancer and to kits of parts useful in such methods.
    Type: Application
    Filed: July 11, 2019
    Publication date: June 10, 2021
    Inventors: Jacobus Adrianus Nieuwenhuijzen, Renske Daniëla Maria Steenbergen, Judith Bosschiether
  • Publication number: 20200032348
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers, said method comprising detection of a methylation classifier consisting of the genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers. The invention further comprises the use of the methylation classifier consisting of genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in such a method and a test kit for the detection of LHX8. ASCL1 and/or ST6GALNAC5 methylation.
    Type: Application
    Filed: March 9, 2018
    Publication date: January 30, 2020
    Inventors: Christophorus Joannes Lambertus Maria MEIJER, Renske Daniëla Maria STEENBERGEN, Petrus Josephus Ferdinandus SNIJDERS, Daniëlle Anne Marie HEIDEMAN
  • Publication number: 20190241963
    Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.
    Type: Application
    Filed: March 31, 2017
    Publication date: August 8, 2019
    Inventors: Willem Frederik Rurup, Loes Irene Segerink, Roderik Adriaan Kraaijenhagen, Herbert Michael Pinedo, Albert Van Den Berg, Renske Daniëla Maria Steenbergen, Jacobus Adrianus Nieuwenhuijzen, Idris Bahce, Geert Kazemier
  • Patent number: 9890432
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: February 13, 2018
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Patent number: 9315866
    Abstract: The inventors now have developed a (molecular) diagnostic marker based on MAL alterations, in particular reduced MAL mRNA and protein expression as well as MAL promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, and high-risk human papillomavirus (HPV)-induced precursor lesions of non-cervical invasive cancers within, cell material obtained via scraping, lavage or by other means and/or tissue. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the gene products thereof as marker for HPV-induced high-grade premalignant lesions, allowing early detection and better treatment option for the individual patient.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: April 19, 2016
    Assignee: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Publication number: 20150284815
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
    Type: Application
    Filed: October 14, 2013
    Publication date: October 8, 2015
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Publication number: 20150225796
    Abstract: The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self-sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV-induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 13, 2015
    Applicant: Self-screen B.V.
    Inventors: Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen, Daniëlle Anne Marie Heideman, Christophorus Joannes Lambertus Maria Meijer
  • Publication number: 20110171628
    Abstract: This invention describes new protocols for screening for cervical carcinomas or high-grade premalignant cervical lesions based on combinations of testing for the presence of high-risk HPV, HPV genotyping, marker analysis, and/or cytology. With these protocols the number of women that have to undergo follow-updiagnostic testing and/or clinical examinations will decrease. Further, the number of false positives and false negatives will decrease.
    Type: Application
    Filed: March 13, 2009
    Publication date: July 14, 2011
    Applicant: Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen, Daniëlle Anne Marie Heideman
  • Publication number: 20110104660
    Abstract: The inventors now have developed a (molecular) diagnostic marker based on MAL alterations, in particular reduced MAL mRNA and protein expression as well as MAL promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, and high-risk human papillomavirus (HPV)-induced precursor lesions of non-cervical invasive cancers within, cell material obtained via scraping, lavage or by other means and/or tissue. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the gene products thereof as marker for HPV-induced high-grade premalignant lesions, allowing early detection and better treatment option for the individual patient.
    Type: Application
    Filed: April 14, 2009
    Publication date: May 5, 2011
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Publication number: 20090203072
    Abstract: This invention provides a method of detecting an HPV-induced invasive cancer or precursor lesion thereof associated with tumor suppressor lung cancer 1 (TSLC1) in a subject in need thereof. The method comprises contacting a cell component of a test cell of the subject with a reagent that detects the level of the cell component in the test cell and determining a modification in the level of the cell component in the test cell as compared with a comparable healthy cell. The cell component indicates the level of TSLC1 in the cell, and a decrease in the level of TSLC1 indicates the presence of an HPV-induced invasive cancer or precursor lesion.
    Type: Application
    Filed: February 11, 2009
    Publication date: August 13, 2009
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Renske Daniela Maria Steenbergen, Petrus Josephus Fernidandus Snijders
  • Patent number: 7501261
    Abstract: The invention is in the field of medicine and is concerned with a molecular diagnostic marker for progression to invasiveness of HPV-induced premalignant lesions and future metastatic potential of HPV-induced premalignant lesions and carcinomas. In particular the present invention relates to the use of the TSLC1 gene as marker for progression to invasive cervical cancer and metastatic potential of cervical lesions. The invention provides methods for detecting HPV-induced invasive cancers and their precursor lesions associated with tumor suppressor lung cancer 1 (TSLC1), comprising contacting a target cellular component of a test cell with a reagent that detects TSLC1 and detecting a reduction in the TSLC1 as compared to that of a comparable normal cell. The invention also provides molecular diagnostic markers for premalignant cervical lesions with invasive potential associated with tumor suppressor lung cancer 1 (TSLC1) in cytologically abnormal cervical smears and/or biopsies.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: March 10, 2009
    Assignee: Stiching Researchfonds Pathologie
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Renske Daniela Maria Steenbergen, Petrus Josephus Ferdinandus Snijders